Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.N30 Pharma has successfully completed Phase I study of N30-201 in healthy volunteers, which it intends to develop for the treatment of reactive and obstructive airway diseases, including cystic fibrosis and asthma.
Subscribe to our email newsletter
The primary endpoint of the study was patient safety and characterization of adverse events, but the company collected pharmacokinetic and pharmacodynamic data of ascending doses of N30-201. N30-201 is a proprietary nebulized formulation of s-nitrosoglutathione (GSNO), an endogenous bronchodilatory molecule that serves as a crucial store of nitric oxide bioactivity in the human airway.
Charles Scoggin, chairman of N30 Pharma, said: “We believe that N30-201 could be an important therapy for the treatment of many respiratory diseases. Determining the safety of acute administration of N30-201 to human subjects is the first step.”